The findings stem from post-hoc analyses of previous trials, which found that 75.1% of patients reached PASI100 after 1 year on bimekizumab.

In addition to decreases in BMI, researchers also reported fewer HS flare ups.

The study found that over 80% of patients who responded to lebrikizumab at week 16 maintained clear or almost-clear skin after 3 years.

A new analysis from phase 3 studies shows Rinvoq's effectiveness for moderate to severe AD with head and neck involvement.

Learn more about the latest in dermatology from Sheila Fallon Friedlander, MD; Melodie Young, MSN, ANP-c; Raj Chovatiya, MD, PhD, MSCI; Julie Harper, MD; and Matthew Zirwas, MD.

Catch up on coverage from the fourth day of the Maui Derm NP+PA Fall 2024 conference in Nashville, Tennessee.

Hilary Baldwin, MD, emphasized involving patients in the decision-making process to create a personalized and cost-effective plan.

In this Maui Derm NP+PA Fall session, Tsao discusses the growing trend of TIL therapy and neoadjuvant treatment for pigmented lesions, as well as atypical clinical presentation.

In her session at Maui Derm NP+PA Fall, Culton also emphasized the importance of accurate and timely diagnosis, as well as upcoming treatment options.

During an interview with Dermatology Times, Zirwas outlined modern allergens such as sulfites, dietary nickel, and acrylates.

Catch up on coverage from the third day of the Maui Derm NP+PA Fall 2024 conference in Nashville, Tennessee.

From dupilumab to OX40s, Zirwas talked about the niche to all atopic dermatitis therapies to make the best decision with your patient.

In a session at Maui Derm NP+PA Fall, Zirwas talked about the newfound discoveries of causation within the AD space.

In his signature Maui Derm NP+PA Fall 2024 session, Shapiro discusses the importance of acting quickly when confronted with a patient who has scarring alopecia.

In a session at Maui Derm NP+PA Fall 2024, Julie Harper, MD, ran through 5 key takeaways for providers managing patients with acne, including where the new triple fixed-dose combination treatment falls in the treatment landscape.

Del Rosso’s cases emphasized the importance of thorough patient evaluation and communication with other health care providers.

Catch up on coverage from the second day of the Maui Derm NP+PA Fall 2024 conference in Nashville, Tennessee.

During his session at Maui Derm NP+PA Fall, Hawkes emphasized the need for careful patient communication and shared his excitement for remibrutinib.

This Maui Derm NP+PA Fall session discusses the latest advancements in hidradenitis suppurativa treatment, the evolving therapeutic landscape, and the critical need for timely diagnosis and aggressive care.

Researchers analyzed APPs treatment and perceptions on AD in studies focusing on patient satisfaction and patients with skin of color.